An experimental stem cell therapy, laromestrocel, has shown positive results in a clinical trial for treating frailty in older adults. The therapy, made from mesenchymal stem cells, improved walking distance in participants and targeted underlying mechanisms of frailty like inflammation. The treatment is still in development, but it shows significant potential in addressing frailty at its biological roots, offering hope beyond current lifestyle interventions.
An experimental stem cell therapy could treat frailty by targeting the condition at its biological roots. Frailty – which raises the risk of falls and infections – is typically only mitigated through lifestyle changes, like doing strength training and balance exercises.
But now, it seems that a novel infusion ofRapid bursts of ageing are causing a total rethink of how we grow old Hare and his colleagues at Longeveron are developing a therapy that they hope will target some of the underlying mechanisms of, such as inflammation and impairment of the metabolic processes that make muscles contract. The therapy – called laromestrocel – is made up of mesenchymal stem cells that can develop into many different types of cells, including muscle and cartilage, taken from healthy bone marrow donors aged 18 to 45.for frailty – which affects around 1 in 4 people aged 65 and over – they have now tested various doses of laromestrocel against a placebo in a larger group of 148 people. The researchers measured how far the participants – who were aged 74 to 76 and had mild-to-moderate frailty – could walk in 6 minutes before and after laromestrocel. They found that a single infusion improved their performance in a dose-dependent fashion, with no serious safety concerns. For instance, those who got the maximum dose could walk 41 metres further than those who received the placebo six months after the infusions – rising to 63 metres at nine months.Your science-backed guide to the easy habits that will help you sleep well, stress less, eat smarter and age better.Laromestrocel inhibits enzymes called matrix metalloproteinases, according to the team, which have a degenerative effect on structural proteins in the blood vessels and other tissues. This means laromestrocel could regenerate the vascular system, which then benefits muscle fibres involved in endurance, says Hare. It did not, however, lead to improvements in walking speed or grip strength. “Clinically, the most important issue is the 6-minute walk distance, which is known to correlate with health status and longevity,” says Hare.at the University of Birmingham in the UK. “I was impressed by the overall change demonstrated in the 6-minute walk time.” What’s more, the trial may have led to a biomarker for frailty, which could help identify people who will benefit from the treatment the most – possibly even before symptoms arise. The researchers screened a panel of eight potential biomarkers that are known to be involved in inflammation and blood vessel formation. When analysing the participants’ blood, they observed that levels of a fragment called sTIE2, which reflects impaired vascular function, decreased progressively with rising doses of laromestrocel.Life expectancy has increased dramatically over the past century, but our years of good health appear not to have kept pace. Now, a new lens on what it means to age well is reshaping our view of our golden years This suggests that people with high sTIE2 could benefit most from the therapy, says Wilson. “Frailty is very heterogeneous,” she says. “I think the most important part of geroprotector medicine going forwards is matching the right patient to the right treatment.” However, she also raised practical concerns about the cost of stem cell therapies and their feasibility. “Given how expensive this is likely to be, I am not sure how you would be able to justify its use when there have been trials of walking programmes, which have improved 6-minute walk test by more than 50 metres,” she says. “My other thought is how difficult it is to obtain stem cells from volunteers. There would need to be a lot of volunteers to treat everyone with frailty.” Hare counters this by saying that various companies are making technological advances to scale up stem cell therapies to reach more people. “There is a lot of work ongoing regarding the ability to make these kinds of stem cells in large quantities, and I am confident the need will be met,” he says.
Stem Cell Therapy Frailty Aging Clinical Trial Mesenchymal Stem Cells
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
This Is What Living With Sickle Cell Actually Looks LikeThe New Black View
Read more »
Got problems? Let L.A. comedians give you live 'therapy' at this confessional-style showCoffee and therapy: Find a hilarious 'support group' at an L.A. cafe show
Read more »
The Valley: Persian Style Exposes MJ and Tommy’s Couples Therapy SessionIn a sneak peek of 'The Valley: Persian Style' season finale, Mercedeh 'MJ' Javid and Tommy Feight head to a tense couples therapy session
Read more »
Therapy dog Ardi patrols Huntsman Cancer Institute halls, bringing comfort to patientsYou can find Cindy and her dog Ardi walking the halls of the Huntsman Cancer Institute. Ardi is a popular celebrity here, he even has his own trading card. But
Read more »
Stem cell patch reverses brain damage in fetuses with spina bifidaThe congenital condition spina bifida is often treated surgically in the womb, but many children still go on to have mobility issues. The addition of a patch made up of stem cells from donated placentas could improve their long-term outcomes
Read more »
Family of Colorado man who died after stem cell injection in Seattle awarded $24MSenior broadcast journalist and newsroom leader delivering award-winning radio news coverage and editorial direction in the Seattle region.
Read more »